Moderna (MRNA) Stock Forecast & Price Target

― Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRNA Analyst Ratings

Hold

1 Buy

13 Hold

2 Sell

Based on 16 analysts giving stock ratings to

Moderna

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRNA Stock 12 Month Forecast

Average Price Target

$841.77

Based on 16 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $841.77 with a high forecast of $1,348.18 and a low forecast of $665.34. The average price target represents a ― change from the last price of ―.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"445":"$445","671":"$671","897":"$897","1123":"$1,123","1349":"$1,349"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1348.18083169,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.35K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":841.7712485576923,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$841.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":665.33599486,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$665.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[445,671,897,1123,1349],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1294,1298.167756283846,1302.3355125676924,1306.5032688515385,1310.6710251353848,1314.8387814192308,1319.006537703077,1323.1742939869232,1327.3420502707693,1331.5098065546154,1335.6775628384617,1339.8453191223077,1344.013075406154,{"y":1348.18083169,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1294,1259.2131729659764,1224.4263459319527,1189.639518897929,1154.8526918639054,1120.0658648298815,1085.279037795858,1050.4922107618343,1015.7053837278106,980.918556693787,946.1317296597633,911.3449026257396,876.5580755917159,{"y":841.7712485576923,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1294,1245.6412303738462,1197.2824607476923,1148.9236911215385,1100.5649214953846,1052.2061518692308,1003.8473822430769,955.4886126169231,907.1298429907692,858.7710733646154,810.4123037384616,762.0535341123077,713.6947644861539,{"y":665.33599486,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":542.82,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":515,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":476.21,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":505.41,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":509,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":446,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":531,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":764.47,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":950,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":895,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":800.01,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":805,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1294,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,348

Average Price Target$841.77

Lowest Price Target$665.34

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Eliana Merle

Barclays

$840.42

Hold

―

Reiterated

07/24/26

Barclays Reaffirms Their Hold Rating on Moderna (MRNA)

Courtney Breen

Bernstein

$787.9

Hold

―

Reiterated

07/22/26

Moderna (MRNA) Receives a Hold from Bernstein

Salveen Richter

Goldman Sachs

$857.93→$1,173.09

Hold

―

Assigned

07/21/26

Moderna price target raised to $67 from $49 at Goldman SachsModerna price target raised to $67 from $49 at Goldman Sachs

Terence Flynn

Morgan Stanley

$577.79→$682.84

Hold

―

Reiterated

07/08/26

Moderna price target raised to $39 from $33 at Morgan StanleyModerna price target raised to $39 from $33 at Morgan Stanley

Alec Stranahan

Bank of America Securities

$595.3→$665.34

Sell

―

Reiterated

07/07/26

Bank of America Securities Reaffirms Their Sell Rating on Moderna (MRNA)

Luca Issi

RBC Capital

$665.34→$787.9

Hold

―

Reiterated

07/07/26

Moderna price target raised to $45 from $38 at RBC CapitalModerna price target raised to $45 from $38 at RBC Capital

Myles Minter

William Blair

―

Hold

―

Reiterated

06/27/26

Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks

Geoff Meacham

Citi

$717.86

Hold

―

Reiterated

06/26/26

Hold Rating Reaffirmed on Moderna as Analyst Highlights High-Risk/High-Reward Pipeline and Keeps Price Target Unchanged at $41

Edward Tenthoff

Piper Sandler

$1,208.11→$1,348.18

Buy

―

Reiterated

06/26/26

Moderna price target raised to $77 from $69 at Piper SandlerModerna price target raised to $77 from $69 at Piper Sandler

Jessica Fye

J.P. Morgan

―

Sell

―

Reiterated

06/18/26

Analysts Conflicted on These Healthcare Names: AbbVie (NYSE: ABBV) and Moderna (NASDAQ: MRNA)

Andrew Tsai

Jefferies

$787.9

Hold

―

Reiterated

06/16/26

Moderna flu vaccine briefing docs 'read favorably,' says JefferiesModerna flu vaccine briefing docs 'read favorably,' says Jefferies

Michael Yee

UBS

$787.9

Hold

―

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Mediwound (NASDAQ: MDWD)

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$787.9

Hold

―

Reiterated

05/06/26

Berenberg Bank Sticks to Its Hold Rating for Moderna (MRNA)

Cory Kasimov

Evercore ISI

$612.81→$875.44

Hold

―

Reiterated

05/04/26

Moderna price target raised to $50 from $35 at Evercore ISIModerna price target raised to $50 from $35 at Evercore ISI

Tyler Van Buren

TD Cowen

$700.35

Hold

―

Reiterated

05/01/26

Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and Stryker (NYSE: SYK)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Eliana Merle

Barclays

$840.42

Hold

―

Reiterated

07/24/26

Barclays Reaffirms Their Hold Rating on Moderna (MRNA)

Courtney Breen

Bernstein

$787.9

Hold

―

Reiterated

07/22/26

Moderna (MRNA) Receives a Hold from Bernstein

Salveen Richter

Goldman Sachs

$857.93→$1,173.09

Hold

―

Assigned

07/21/26

Moderna price target raised to $67 from $49 at Goldman SachsModerna price target raised to $67 from $49 at Goldman Sachs

Terence Flynn

Morgan Stanley

$577.79→$682.84

Hold

―

Reiterated

07/08/26

Moderna price target raised to $39 from $33 at Morgan StanleyModerna price target raised to $39 from $33 at Morgan Stanley

Alec Stranahan

Bank of America Securities

$595.3→$665.34

Sell

―

Reiterated

07/07/26

Bank of America Securities Reaffirms Their Sell Rating on Moderna (MRNA)

Luca Issi

RBC Capital

$665.34→$787.9

Hold

―

Reiterated

07/07/26

Moderna price target raised to $45 from $38 at RBC CapitalModerna price target raised to $45 from $38 at RBC Capital

Myles Minter

William Blair

―

Hold

―

Reiterated

06/27/26

Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks

Geoff Meacham

Citi

$717.86

Hold

―

Reiterated

06/26/26

Hold Rating Reaffirmed on Moderna as Analyst Highlights High-Risk/High-Reward Pipeline and Keeps Price Target Unchanged at $41

Edward Tenthoff

Piper Sandler

$1,208.11→$1,348.18

Buy

―

Reiterated

06/26/26

Moderna price target raised to $77 from $69 at Piper SandlerModerna price target raised to $77 from $69 at Piper Sandler

Jessica Fye

J.P. Morgan

―

Sell

―

Reiterated

06/18/26

Analysts Conflicted on These Healthcare Names: AbbVie (NYSE: ABBV) and Moderna (NASDAQ: MRNA)

Andrew Tsai

Jefferies

$787.9

Hold

―

Reiterated

06/16/26

Moderna flu vaccine briefing docs 'read favorably,' says JefferiesModerna flu vaccine briefing docs 'read favorably,' says Jefferies

Michael Yee

UBS

$787.9

Hold

―

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Mediwound (NASDAQ: MDWD)

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$787.9

Hold

―

Reiterated

05/06/26

Berenberg Bank Sticks to Its Hold Rating for Moderna (MRNA)

Cory Kasimov

Evercore ISI

$612.81→$875.44

Hold

―

Reiterated

05/04/26

Moderna price target raised to $50 from $35 at Evercore ISIModerna price target raised to $50 from $35 at Evercore ISI

Tyler Van Buren

TD Cowen

$700.35

Hold

―

Reiterated

05/01/26

Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and Stryker (NYSE: SYK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AORTArtivion

ENOVEnovis

GKOSGlaukos

IFRXInflaRx

BKDBrookdale Senior Living

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Moderna

3 Months

Mani ForooharLeerink Partners

Success Rate

29/49 ratings generated profit

Average Return

-10.15%

Copying Mani Foroohar's trades and holding each position for 3 Months would result in 59.18% of your transactions generating a profit, with an average return of -10.15% per trade.

1 Year

Mani ForooharLeerink Partners

Success Rate

32/49 ratings generated profit

Average Return

-17.80%

Copying Mani Foroohar's trades and holding each position for 1 Year would result in 65.31% of your transactions generating a profit, with an average return of -17.80% per trade.

2 Years

Mani ForooharLeerink Partners

Success Rate

34/49 ratings generated profit

Average Return

+4.35%

Copying Mani Foroohar's trades and holding each position for 2 Years would result in 69.39% of your transactions generating a profit, with an average return of +4.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRNA Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRNA has received 3 Buy Ratings, 38 Hold Ratings, and 11 Sell Ratings. MRNA average Analyst price target in the past 3 months is 841.77.

Each month's total comprises the sum of three months' worth of ratings.

MRNA Financial Forecast

MRNA Earnings Forecast

Next quarter’s earnings estimate for MRNA is -$35.63 with a range of -$41.15 to -$28.01. The previous quarter’s EPS was -$59.53. MRNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year MRNA has Performed in-line its overall industry.

MRNA Sales Forecast

Next quarter’s sales forecast for MRNA is $1.80B with a range of $1.31B to $2.71B. The previous quarter’s sales results were $6.81B. MRNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year MRNA has Performed in-line its overall industry.

MRNA Stock Forecast FAQ

What is MX:MRNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Moderna’s 12-month average price target is 841.77.

What is MX:MRNA’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for MX:MRNA, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Moderna a Buy, Sell or Hold?

Moderna has a consensus rating of Hold, which is based on 1 buy ratings, 13 hold ratings and 2 sell ratings.

What is Moderna’s share price target?

The average share price target for Moderna is 841.77. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $1,348.18 ,and the lowest forecast is $665.34. The average share price target represents N/A Increase from the current price of N/A.

What do analysts say about Moderna?

Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Moderna?

To buy shares of MX:MRNA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Moderna (MRNA) Stock Forecast & Price Target

MRNA Analyst Ratings

MRNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Moderna

MRNA Analyst Recommendation Trends

MRNA Financial Forecast

MRNA Earnings Forecast

MRNA Sales Forecast

MRNA Stock Forecast FAQ

Detailed List of Analyst Forecasts